Metformin and Systemic Inflammation in HIV

Inclusion Criteria: * Both sexes, * Age ≥18 years of age * With a diagnosis of HIV-1 infection, * That they are receiving TARE for at least 12 months (time necessary to establish a stable reservoir), * Patients with undetectable viral load (\<40 copies / mL) for at least 12 months, * Have a CD4 + level\> 200 cells / μL, * That they do not have a diagnosis of co-infection with HCV or HBV, * Patients who do not have a severe alcohol intake (\<21 glasses / week in men and \<14 glasses / week in women), * Patients who do not use drugs during the last 90 days prior to the screening visit, or during the study, * Who wish to participate voluntarily in the study and give their written consent. Exclusion Criteria: * Individuals with a known hypersensitivity / allergy to metformin. * Patients with contraindications to the use of metformin \*. * Individuals who are actively involved in an experimental therapy study or who have received experimental therapy in the last 6 months. * People suffering from stage IV-V chronic kidney disease, uncontrolled heart failure or active infections. * Individuals with diabetes mellitus (according to the criteria of the American Diabetes Association \*). * Patients with indication for the use of statins, aspirin or immunomodulators.